Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Reunion Neuroscience Inc.

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
From Reunion Neuroscience Inc.
Via GlobeNewswire
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
From Reunion Neuroscience Inc.
Via GlobeNewswire
Tickers REUN TSX:REUN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.